Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020
ConclusionsDOACs have replaced warfarin as the preferred OAC in the US. The increased costs associated with DOAC use may decline when generic formulations are approved.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Coumadin | Heart | Insurance | Pradaxa | Study | USA Health | Warfarin